Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 199.07

-3.4%

Nov 20 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Flagrante Delictu who wrote (15558)	2/21/1998 7:52:00 AM
From: Henry Niman	Read Replies (2) of 32384

Speaking of LLY, they and MRK are mentioned in next week's Barron's in the osteoporosis article. For drug treatment, only Evista and Fosamax are mentioned. In the US there are 20 million women and 5 million men with osteoporosis. Fosamax sales are in the $1/2 Billion range and Evista sales are causing huge gyrations in LLY's stock price. No mention of LGND, either directly or through partners (PFE, AHP) who have SERMs in the clinic (Droloxifene, CP-366,156) or slated to enter this quarter (TSE424). There is also no mention of combing Targretin with Evista to improve results (sales). Both Fosamax and Evista are almost as good as estrogen for slowing bone loss, and both seem to have a better safety profile with regard to stimulating breast tissue (but I don't think that either provide the cardio-protective benefit of estrogen). AHP is mentioned in the area of patching up fractions, and the Hybritech Division of Beckman Instruments is mentioned in the diagnostic area.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next